Edition:
India

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

8.17USD
19 Jan 2018
Change (% chg)

$0.25 (+3.16%)
Prev Close
$7.92
Open
$7.90
Day's High
$8.55
Day's Low
$7.85
Volume
16,455
Avg. Vol
14,779
52-wk High
$21.59
52-wk Low
$6.61

Latest Key Developments (Source: Significant Developments)

Gemphire Therapeutics Announces Start Of First Nash Proof-Of-Concept Clinical Trial
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE THERAPEUTICS ANNOUNCES INITIATION OF ITS FIRST NASH PROOF-OF-CONCEPT CLINICAL TRIAL AND ITS DIFFERENTIATED NASH PROGRAM.GEMPHIRE THERAPEUTICS INC - NASH PROGRAM EXPECTED TO BE PHASE 2B READY BY YEAR-END 2018.GEMPHIRE THERAPEUTICS INC - PLANS TO LAUNCH A SECOND PHASE 2A PROOF-OF-CONCEPT TRIAL IN NASH EARLY IN 2018.  Full Article

Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Gemphire Therapeutics Inc :Gemphire Therapeutics Inc qtrly loss per share $0.82‍​.  Full Article

Gemphire Therapeutics announces closing of initial public offering
Thursday, 11 Aug 2016 

Gemphire Therapeutics Inc :Gemphire therapeutics announces closing of initial public offering.  Full Article

Gemphire Therapeutics shares open at $9.25 in debut
Friday, 5 Aug 2016 

: Gemphire Therapeutics Inc shares open at $9.25 in debut, below IPO price of $10.00 per share Further company coverage: [GEMP.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Gemphire Therapeutics says public offering of 3 mln shares at $10/shr
Friday, 5 Aug 2016 

Gemphire Therapeutics Inc : Initial public offering of 3 million shares of its common stock at a price to public of $10.00 per share .Gemphire therapeutics announces pricing of initial public offering.  Full Article

Gemphire Therapeutics sees IPO priced between $11-$13 per share
Monday, 13 Jun 2016 

Gemphire Therapeutics Inc :Sees IPO of 3.75 million shares of co's common stock to be priced between $11.00 and $13.00 per share.  Full Article

BRIEF-Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr

* Gemphire Therapeutics Inc qtrly loss per share $0.82‍​ Source: (http://bit.ly/2iaJuNF) Further company coverage: